Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.98 USD | +0.92% | -12.75% | +53.25% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
Business Summary
Number of employees: 30
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Enzyme Therapeutics
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -61.96% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -61.96% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Chief Tech/Sci/R&D Officer | 56 | 14-01-31 | |
Mira Huyghe
PRN | Corporate Officer/Principal | - | Nov. 26 |
Deanna Nguyen
PRN | Corporate Officer/Principal | - | Nov. 26 |
Joshua Friedman
PRN | Corporate Officer/Principal | - | Nov. 26 |
General Counsel | 41 | 23-09-04 | |
Paul Fehlner
PRN | Corporate Officer/Principal | 61 | Nov. 26 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Peter Harwin
BRD | Director/Board Member | 38 | 23-06-21 |
Laurie Stelzer
BRD | Director/Board Member | 56 | Nov. 26 |
Director/Board Member | 34 | 23-06-21 | |
Mark Mckenna
BRD | Director/Board Member | 44 | Jan. 31 |
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 271,625 | 0 | 0 | 88.69 % |
Stock B | 1 | 40,283,414 | 35,728,470 ( 88.69 %) | 0 | |
Stock C | 0 | 437,037 | 0 | 0 |
Company contact information
Spyre Therapeutics, Inc.
Building 17 221 Crescent Street
02453, Waltham
+617 651 5940
http://www.aeglea.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.25% | 1.33B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- SYRE Stock
- Company Spyre Therapeutics, Inc.